[HTML][HTML] Molecular Mechanism for Malignant Progression of Gastric Cancer Within the Tumor Microenvironment
T Matsuoka, M Yashiro - International Journal of Molecular Sciences, 2024 - mdpi.com
Gastric cancer (GC) is one of the most common cancers worldwide. Most patients are
diagnosed at the progressive stage of GC, and progress in the development of effective anti …
diagnosed at the progressive stage of GC, and progress in the development of effective anti …
Identification and validation VAT1 in gastric cancer through bioinformatics and experimental analysis
Y Hu, Y Du, Z Qiu, P Mao, M Da - International Immunopharmacology, 2025 - Elsevier
This study investigated the expression pattern of Vesicular Amine Transporter 1 (VAT1) in
gastric cancer (GC) and its impact on prognosis, alongside evaluating its potential as a …
gastric cancer (GC) and its impact on prognosis, alongside evaluating its potential as a …
[HTML][HTML] Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study
V Massa, F Signorini, F Salani, ME Filice… - ESMO Gastrointestinal …, 2024 - Elsevier
Background Programmed death-ligand 1 (PD-L1) expression serves as a predictive
biomarker for response to immune checkpoint inhibitors (ICIs) in metastatic …
biomarker for response to immune checkpoint inhibitors (ICIs) in metastatic …
[PDF][PDF] Prediction of lymph node metastasis risk by M2 tumor associated macrophages in colorectal cancer tissue
X ZHU, Z LONG, S CAO - Chin J Clin Res, 2024 - hkbb4ef4.pic16.websiteonline.cn
Abstract： Objective To investigate the risk of lymph node metastasis (LNM) in colorectal
cancer (CRC) based on the M2 macrophage activity biomarker soluble CD163 (sCD163) …
cancer (CRC) based on the M2 macrophage activity biomarker soluble CD163 (sCD163) …